New antibody IMP761 tested for safety in healthy volunteers
Knowledge-focused
Recruiting now
This early-phase trial tests whether a new drug called IMP761 is safe and tolerable in 79 healthy adults aged 18-55. Participants receive either IMP761 or a placebo intravenously, along with a harmless immune challenge (KLH) to see how the drug affects immune responses. The study…
Phase: PHASE1 • Sponsor: Immutep S.A.S. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC